logo

For the Inventor, By the Inventor

Smørum, Denmark

Gunnar M Olsen

USPTO Granted Patents = 72 

 

 

Average Co-Inventor Count = 4.8

ph-index = 8

Forward Citations = 179(Granted Patents)

Forward Citations (Not Self Cited) = 161(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Copenhagen, DK (1999 - 2000)
  • Frederiksberg, DK (2002 - 2007)
  • Frederiksberg, DE (2007)
  • Smoerum, DK (2007 - 2008)
  • Ballerup, DK (2002 - 2012)
  • Smørum, DK (2010 - 2013)
  • Smorum, DK (2011 - 2013)
  • Smerum, DK (2013)

Company Filing History:

goldMedal72 out of 206 
 
Neurosearch A/s
 patents
silverMedal1 out of 4,179 
 
Abbott Laboratories Corporation
 patents
where one patent can have more than one assignee

Years Active: 1999-2013

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Monoamine Neurotransmitter Re-Uptake Inhibitors
Cholinergic Receptor Modulators
Nicotinic Acetylcholine Receptor Agonists
Diazabicyclic Aryl Derivatives
Oxadiazolyl Compounds
Pyrimidine Derivatives
Azabicyclic Aryl Derivatives
Quinuclidine Derivatives
Dimeric Azacyclic Compounds
Alkyl Substituted Piperidine Derivatives
Chromen-2-One Derivatives
Heteroaryl Diazacycloalkanes
72 patents (USPTO):Explore Patents
1. 8410271 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2013-04-02),
2. 8372832 - 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use (2013-02-12),
3. 8343960 - 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use (2013-01-01),
4. 8263617 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2012-09-11),
5. 8236793 - Diazabicyclic aryl derivatives as cholinergic receptor modulators (2012-08-07),
6. 8173658 - Diazabicycylic aryl derivatives and their medical use (2012-05-08),
7. 8158619 - 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use (2012-04-17),
8. 8148365 - 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use (2012-04-03),
9. 8110588 - 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors (2012-02-07),
10. 8110586 - 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2012-02-07),
11. 8101598 - 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use (2012-01-24),
12. 8022081 - Naphthyl substituted azabicyclo derivatives and their use as monomine neurotransmitter re-uptake inhibitors (2011-09-20),
13. 8017631 - Oxadiazole derivatives and their medical use (2011-09-13),
14. 7989470 - 3,8-substituted 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2011-08-02),
15. 7973082 - Substituted aryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors (2011-07-05),

Title: Innovations and Patents of Gunnar M. Olsen

Introduction

Gunnar M. Olsen, based in Smørum, Denmark, is a prominent inventor with a remarkable portfolio of 72 patents. His contributions to pharmacology and neuroscience have positioned him as a significant figure in the research and development of novel therapeutic compounds.

Latest Patents

Among his latest inventions, Gunnar M. Olsen has developed chromen-2-one derivatives designed to act as monoamine neurotransmitter re-uptake inhibitors. This groundbreaking invention not only explores the efficacy of chromen-2-one derivatives but also expands upon their applications in therapeutic methodologies and pharmaceutical compositions. Another noteworthy patent encompasses 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical applications. These novel derivatives serve as cholinergic ligands at the nicotinic acetylcholine receptors and as modulators of monoamine receptors and transporters. The pharmacological profiles of these compounds promise potential treatments for a range of diseases, including disorders related to the central and peripheral nervous systems, inflammation, and neuro-degeneration.

Career Highlights

Throughout his career, Gunnar M. Olsen has collaborated with reputable companies such as Neurosearch A/S and Abbott Laboratories Corporation, demonstrating his commitment to advancing medical science through innovation.

Collaborations

Gunnar has worked alongside notable colleagues, including Dan Peters and Elsebet Østergaard Nielsen. Their collective efforts have contributed to the advancement of new therapeutic solutions, further enhancing the impact of their research and inventions.

Conclusion

Gunnar M. Olsen's extensive patent portfolio and his pioneering work in pharmacology and neuroscience exemplify the spirit of innovation. His inventions not only provide insights into complex biological systems but also hold potential for treating various medical conditions, underscoring the vital role that inventors like him play in advancing healthcare and scientific knowledge.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…